Registry-based randomized clinical trials in cardiology: opportunities and challenges

Registry-based randomized clinical trials in cardiology: opportunities and challenges

INTRODUCTION The randomized clinical trial (RCT) has become the gold standard for evaluating clinical treatments thanks to its low selection bias and unknown confounders. However, good clinical practice guidelines and demands from regulatory agencies have become so elaborate over time that, basicall...

Full description

Bibliographic Details
Main Author: David Erlinge
Format: Article
Language:English
Published: Permanyer 2021-08-01
Series:REC: Interventional Cardiology (English Ed.)
Online Access:https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=625
id doaj-0e28e4976b7a4002ba68631afa720d92
record_format Article
spelling doaj-0e28e4976b7a4002ba68631afa720d922021-07-27T09:34:20ZengPermanyerREC: Interventional Cardiology (English Ed.)2604-73222021-08-013315716010.24875/RECICE.M21000205Registry-based randomized clinical trials in cardiology: opportunities and challengesDavid Erlinge0Department of Cardiology, Clinical Sciences, Lund University, Lund, SwedenINTRODUCTION The randomized clinical trial (RCT) has become the gold standard for evaluating clinical treatments thanks to its low selection bias and unknown confounders. However, good clinical practice guidelines and demands from regulatory agencies have become so elaborate over time that, basically, only big pharmaceutical companies have the resources to conduct large RCTs. Therefore, important questions raised by academic scientists could be impossible to test in clinical trials.https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=625
collection DOAJ
language English
format Article
sources DOAJ
author David Erlinge
spellingShingle David Erlinge
Registry-based randomized clinical trials in cardiology: opportunities and challenges
REC: Interventional Cardiology (English Ed.)
author_facet David Erlinge
author_sort David Erlinge
title Registry-based randomized clinical trials in cardiology: opportunities and challenges
title_short Registry-based randomized clinical trials in cardiology: opportunities and challenges
title_full Registry-based randomized clinical trials in cardiology: opportunities and challenges
title_fullStr Registry-based randomized clinical trials in cardiology: opportunities and challenges
title_full_unstemmed Registry-based randomized clinical trials in cardiology: opportunities and challenges
title_sort registry-based randomized clinical trials in cardiology: opportunities and challenges
publisher Permanyer
series REC: Interventional Cardiology (English Ed.)
issn 2604-7322
publishDate 2021-08-01
description INTRODUCTION The randomized clinical trial (RCT) has become the gold standard for evaluating clinical treatments thanks to its low selection bias and unknown confounders. However, good clinical practice guidelines and demands from regulatory agencies have become so elaborate over time that, basically, only big pharmaceutical companies have the resources to conduct large RCTs. Therefore, important questions raised by academic scientists could be impossible to test in clinical trials.
url https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=625
work_keys_str_mv AT daviderlinge registrybasedrandomizedclinicaltrialsincardiologyopportunitiesandchallenges
_version_ 1721279568552132608

Similar Items